Tag Archives: delamanid

Access to medicine, diagnostics and human rights . . . We’re reading how to fight TB

By on .

Just 2 percent of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments that could save their lives – Remember the excitement a couple of years back when the first new kinds of drugs to treat TB to be developed in half a century were approved? When delamanid […]

TB advocates call on organizations, leaders to work together, speed access to existing treatments for drug resistant tuberculosis

By on .

They would like an answer on March 24 When World TB Day next Tuesday commemorates the discovery in 1882 of the bacteria that causes the disease, announcements and op-ed pieces will note the progress that has been made since, and will certainly call for more. A group of 89 organizations that last week sent a […]

Tuberculosis R&D must be U.S. diplomatic priority, say global health leaders

By on .

Along with maintaining funding for fighting global tuberculosis, the United States government must better coordinate with the most affected countries on TB research and development, said global health leaders Monday at a Center for Strategic and International Studies event in Washington, examining challenges to global tuberculosis efforts. This point, along with the recommendation that the […]

TAG’s TB drug guide aims to equip activists

By on .

While the impact of tuberculosis grew over the last decades of the 20th century, with drug resistant forms of the disease and HIV fueling its spread and slowing cures, the drugs used to treat TB have not changed. Bedaquiline and delaminid are the only new TB drugs to have been approved in over forty years, […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]

Access to treatments for MDR TB, hepatitis C, other health threats set to expand with UNITAID grants targeting market barriers

By on .

The first new tuberculosis drug in more than 40 years, a treatment for hepatitis C currently priced in the United States at $84,000, and an early infant diagnostic test for HIV are among the breakthrough medicines and technologies the global health financing organization UNITAID is aiming to make available to people in low- and middle-income […]

Long road to effective TB treatment hits speed bumps: Regulatory refusal of one TB drug candidate, stalled progress on another

By on .

Momentum toward gathering an effective arsenal of treatment for tuberculosis may have gathered speed in recent years, the 2013 Pipeline Report jointly released by the Treatment Action Group and HIV i-base in June pointed out, yet it falls far short of what people sick and infected with TB worldwide need now. Case in point, the […]

Wrapping up CROI 2013, Part I: TB on the verge, VOICE trial point to future research needs, sequestration consequence points to rough road ahead

By on .

Science Speaks spent March 3 – 6 at the Conference on Retroviruses and Opportunistic Infections, covering breaking research news and discussions. Today and tomorrow we will wrap up with summaries of sessions, and questions they raised. Today Science Speaks will look at a obstacle for researchers, while presentations pointed to directions for future studies First […]

TB drug trial yields gains in drug-resistant disease treatment

By on .

A study following patients who had  participated in a trial of a potential new treatment for drug-resistant tuberculosis has shown heartening results, with nearly three-quarters of patients who took the medicine for six months or longer showing “favorable outcomes”  — cured  or completed treatment —  according to a study published in the European Respiratory Journal. […]

Drug maker seeks approval for use against multidrug-resistant tuberculosis

By on .

Makers of an investigational tuberculosis drug that has been urged for “compassionate use” approval in South Africa have applied to the European Medicines Agency to market the medicine as part of a combination therapy for multidrug-resistant tuberculosis. “If approved, bedaquiline could be one of the first drugs with a new mechanism of action for tuberculosis […]